Back to Newsroom

Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis

DUNDEE, UK and ROSCOFF, France, June 29, 2015 (GLOBE NEWSWIRE) — Cyclacel Ltd, a wholly owned subsidiary of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel”) and ManRos Therapeutics SA (“ManRos”) announced the execution of a collaboration, licensing and supply agreement for the exclusive development and commercialisation of Cyclacel’s oral seliciclib capsules by ManRos as a treatment for cystic fibrosis (CF). Among other terms of the agreement ManRos licensed rights to Cyclacel’s proprietary clinical data to enable clinical development of seliciclib for cystic fibrosis indications. The agreement provides for Cyclacel supply of seliciclib investigational product for initial and later stage clinical trials of seliciclib in CF and technical assistance related to Cyclacel’s know-how to facilitate these trials. Cyclacel will receive an up-front payment, milestone payments and tiered royalties, if seliciclib is commercialized for the treatment of CF. Financial details were not disclosed.

Click here to read more